CN105814043B - 用作tnf活性调节剂的三唑并吡啶衍生物 - Google Patents

用作tnf活性调节剂的三唑并吡啶衍生物 Download PDF

Info

Publication number
CN105814043B
CN105814043B CN201480067043.XA CN201480067043A CN105814043B CN 105814043 B CN105814043 B CN 105814043B CN 201480067043 A CN201480067043 A CN 201480067043A CN 105814043 B CN105814043 B CN 105814043B
Authority
CN
China
Prior art keywords
base
alkyl
methyl
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480067043.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105814043A (zh
Inventor
D·C·布鲁金斯
V·E·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN105814043A publication Critical patent/CN105814043A/zh
Application granted granted Critical
Publication of CN105814043B publication Critical patent/CN105814043B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480067043.XA 2013-12-09 2014-12-08 用作tnf活性调节剂的三唑并吡啶衍生物 Expired - Fee Related CN105814043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1321742.7 2013-12-09
GBGB1321742.7A GB201321742D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
PCT/EP2014/076832 WO2015086496A1 (en) 2013-12-09 2014-12-08 Triazolopyridine derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
CN105814043A CN105814043A (zh) 2016-07-27
CN105814043B true CN105814043B (zh) 2019-05-17

Family

ID=50000425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480067043.XA Expired - Fee Related CN105814043B (zh) 2013-12-09 2014-12-08 用作tnf活性调节剂的三唑并吡啶衍生物

Country Status (11)

Country Link
US (1) US9850240B2 (enExample)
EP (1) EP3080109B1 (enExample)
JP (1) JP6426185B2 (enExample)
CN (1) CN105814043B (enExample)
BR (1) BR112016011844B1 (enExample)
CA (1) CA2931578C (enExample)
ES (1) ES2730942T3 (enExample)
GB (1) GB201321742D0 (enExample)
RU (1) RU2677697C1 (enExample)
TR (1) TR201907702T4 (enExample)
WO (1) WO2015086496A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN108137609B (zh) 2015-08-03 2021-07-16 百时美施贵宝公司 用作TNFα的调节剂的环状化合物
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281750A1 (en) * 2005-06-09 2006-12-14 Li James J Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
US20090093516A1 (en) * 2007-10-01 2009-04-09 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
FR2933980A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
WO2010022081A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010022076A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103130792A (zh) * 2011-11-30 2013-06-05 江苏正大天晴药业股份有限公司 一种2-氨基噻唑类化合物
WO2013083206A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
WO2013138687A1 (en) * 2012-03-16 2013-09-19 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
DE10038019A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
KR20030080087A (ko) * 2001-03-09 2003-10-10 화이자 프로덕츠 인코포레이티드 항염증제로서의 트리아졸로피리딘
CN2783538Y (zh) 2004-08-04 2006-05-24 蒋沛康 无电线电池按扣
EP1786811A2 (en) * 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
AU2009272516A1 (en) * 2008-07-18 2010-01-21 Sanofi-Aventis Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
CN102395586A (zh) * 2009-02-17 2012-03-28 奇斯药制品公司 作为p38map激酶抑制剂的三唑并吡啶衍生物
SMT201700456T1 (it) * 2009-07-27 2017-11-15 Gilead Sciences Inc Composti eterociclici fusi come modulatori dei canali ionici
FR2966471A1 (fr) * 2010-09-20 2012-04-27 Valeo Vision Piece de vehicule automobile en materiau a base de polymere (s) traite en surface
EP2755976B1 (en) * 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US9340549B2 (en) * 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
TR201807207T4 (tr) 2012-06-11 2018-06-21 Ucb Biopharma Sprl Tnf-alfa modüle edici benzimidazol bileşikleri.
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281750A1 (en) * 2005-06-09 2006-12-14 Li James J Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
US20090093516A1 (en) * 2007-10-01 2009-04-09 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
FR2933980A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
WO2010022081A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010022076A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103130792A (zh) * 2011-11-30 2013-06-05 江苏正大天晴药业股份有限公司 一种2-氨基噻唑类化合物
WO2013083206A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
WO2013138687A1 (en) * 2012-03-16 2013-09-19 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2

Also Published As

Publication number Publication date
GB201321742D0 (en) 2014-01-22
JP6426185B2 (ja) 2018-11-21
EP3080109B1 (en) 2019-05-15
WO2015086496A1 (en) 2015-06-18
BR112016011844A2 (enExample) 2017-08-08
CA2931578C (en) 2021-10-26
EP3080109A1 (en) 2016-10-19
ES2730942T3 (es) 2019-11-13
RU2677697C1 (ru) 2019-01-21
US20160304512A1 (en) 2016-10-20
US9850240B2 (en) 2017-12-26
TR201907702T4 (tr) 2019-06-21
CA2931578A1 (en) 2015-06-18
CN105814043A (zh) 2016-07-27
RU2016127228A (ru) 2018-01-23
BR112016011844B1 (pt) 2022-08-16
JP2016539971A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
CN105814041B (zh) 用作tnf活性调节剂的苯并三唑衍生物
CN105814043B (zh) 用作tnf活性调节剂的三唑并吡啶衍生物
CN105814025B (zh) 用作tnf活性调节剂的四氢苯并咪唑衍生物
JP7554672B2 (ja) Ｉｒａｋ分解剤およびそれらの使用
CN112135824B (zh) 作为免疫调节剂的杂环化合物
CN102971317B (zh) 四氢-吡啶并-嘧啶衍生物
CN102015705B (zh) 稠合的杂环衍生物及其用途
CN105189494B (zh) 作为ssao抑制剂的咪唑并[4,5‑c]吡啶和吡咯并[2,3‑c]吡啶衍生物
CA3150108A1 (en) Hpk1 antagonists and uses thereof
KR20220145325A (ko) Irak 분해제 및 이의 용도
CA3121236A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
JP2022516401A (ja) Ｉｒａｋ分解剤およびそれらの使用
WO2020251972A1 (en) Smarca degraders and uses thereof
CN109195969A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
AU2018389145B2 (en) Exo-aza spiro inhibitors of menin-MLL interaction
KR20160135283A (ko) 5-치환된 인다졸-3-카르복스아미드 및 이의 제조 및 용도
EP3833439B1 (en) Benzimidazole inhibitors of pad enzymes
BR112020015328A2 (pt) Inibidores de gcn2 e usos dos mesmos
CA3192393A1 (en) Piperidinyl small molecule degraders of helios and methods of use
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
TW201016676A (en) Heterocyclic derivatives and methods of use thereof
KR20230130179A (ko) Irak 분해제 및 그 용도
CN109219609A (zh) 作为tnf活性调节剂的稠合六环咪唑衍生物
CN109195968A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
TW201000476A (en) Dual pharmacophores-PDE4-muscarinic antagonistics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Brussels

Patentee after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Patentee before: UCB BIOPHARMA SPRL

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190517

CF01 Termination of patent right due to non-payment of annual fee